Traditional ELISA methods are highly sensitive, but they require multiple steps of adding antibodies, washing, and adding enzymatic substrates. The complexity of ELISA assays also requires technicians and/or expensive laboratory equipment.
Stanford researchers have developed a robot-assisted mouse positioning system (RAMPS) that enables conformal, pluridirectional FLASH radiotherapy studies in small animals.
Stanford researchers have developed a modular bioconjugation platform that improves the potency and selectivity of antibody-drug conjugates (ADCs) by enhancing their lysosomal internalization.
Stanford researchers have developed a laser-assisted digital manufacturing platform to generate soft and stretchable microstructured components for next-generation force sensors.
Researchers at Stanford have developed TRIM3D (Tissue-Referenced Integrated Micromachining in 3D), a precision tissue extraction platform that couples 3D pathology imaging with guided physical retrieval of specific tissue regions.
Researchers at Stanford have developed a unified, AI-augmented governance platform purpose-built for the clinical, research, and educational operations of academic medical centers (AMCs).
Stanford researchers have designed a microfluidic method for improved control of chemical reactions on-chip using isotachophoresis (ITP). This method allows for simultaneous reaction and separation of reaction products and/or reactants.
Researchers in Prof. Juan Santiago's laboratory have developed a modular on-chip isotachophoresis (ITP) system to extend ITP capabilities to include sensitive and selective extraction of nucleic acids.
An interdisciplinary team of Stanford researchers has developed a novel microfluidic technique to extract and purify RNA, DNA or proteins directly from cell lysate.
Researchers at Stanford have developed orthoTeplizumab, an antibody that selectively recognizes engineered T cells without binding a patient's own T cells.
Researchers at Stanford have developed anti-idiotypic antibodies that reverse anti-CD3 monoclonal antibody therapy, giving clinicians control over the depth and timing of T cell depletion before adoptive cell therapy.
Stanford scientists have developed a microfluidic device that uses isotachophoresis to automate every step of nucleic acid testing, from raw sample to readout, and to run multiple reactions in parallel on a single chip with no moving parts.